feed,title,long_url,short_url
Benzinga,Summit Therapeutics' Lung Cancer Therapy Ivonescimab Shows Improved Progression-Free Survival Versus Merck's Multi-Billion Keytruda In China Study,https://benzinga.com/general/biotech/24/05/39112586/summit-therapeutics-lung-cancer-therapy-ivonescimab-shows-improved-progression-free-survival-vers,https://da.gd/7EKS5
